Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from WuXi XDC Cayman, Inc. ( (HK:2268) ) is now available.
Citigroup Global Markets Asia Limited, on behalf of an offeror, has launched a voluntary conditional cash offer to acquire all issued shares of WuXi XDC Cayman, Inc. not already owned by the offeror and its concert parties, as well as to cancel all outstanding share options, at HK$4.00 per share. The offer price represents a premium of about 99% over the undisturbed closing price of HK$2.01, and the offeror has stated it will not increase either the share offer price or the option cancellation price, positioning this as a potentially major transaction for the offeror and a disclosable transaction for WuXi Biologics while setting a clear ceiling for shareholders and option holders considering whether to tender.
The most recent analyst rating on (HK:2268) stock is a Buy with a HK$90.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
More about WuXi XDC Cayman, Inc.
WuXi XDC Cayman, Inc. is a Hong Kong–listed company in the biopharmaceutical/biologics-related services sector, associated with WuXi Biologics, focusing on providing contract research, development and manufacturing solutions for innovative biologic and related therapies to global pharmaceutical and biotechnology clients.
Average Trading Volume: 4,547,644
Technical Sentiment Signal: Buy
Current Market Cap: HK$89.5B
For an in-depth examination of 2268 stock, go to TipRanks’ Overview page.